{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:40:45Z","timestamp":1789897245035,"version":"4.0.1"},"reference-count":138,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T00:00:00Z","timestamp":1462320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008900","name":"University of South Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31460312"],"award-info":[{"award-number":["31460312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31360285"],"award-info":[{"award-number":["31360285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Human Aurora kinases, including Aurora kinase A (\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    ), B (\n                    <jats:styled-content style=\"fixed-case\">AURKB<\/jats:styled-content>\n                    ), and C (\n                    <jats:styled-content style=\"fixed-case\">AURKC<\/jats:styled-content>\n                    ), play an essential role in mitotic events such as monitoring of the mitotic checkpoint, creation of bipolar mitotic spindle and alignment of centrosomes on it, also regulating centrosome separation, bio\u2010orientation of chromosomes and cytokinesis.\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    and\n                    <jats:styled-content style=\"fixed-case\">AURKB<\/jats:styled-content>\n                    are key regulators of mitosis and centrosome via polymerizing microfilaments and controlling chromatid segregation. In particular,\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    plays critical roles in the regulation of mitotic entry, centrosome function, bipolar spindle assembly, and chromosome segregation.\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    has been found to be overexpressed in various solid and haematological cancers and has been linked with poor prognosis. Its important role in cancer initiation, growth, and metastasis has brought the focus to search for potent and selective\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    inhibitors for cancer treatment.\n                    <jats:styled-content style=\"fixed-case\">MLN<\/jats:styled-content>\n                    8237, also known as alisertib, is one selective\n                    <jats:styled-content style=\"fixed-case\">AURKA<\/jats:styled-content>\n                    inhibitor that has shown remarkable anticancer effects in preclinical studies. Alisertib exhibits favourable pharmacokinetic properties. Alisertib has generally showed good partial response rates of 4\u201352% and good safety profiles in Phase I and\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    trials when it is solely administered as well as combined with cytotoxic chemotherapeutic drugs. Recently, the multicentre, randomized Phase\n                    <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                    study of alisertib in patients with relapsed or refractory peripheral T\u2010cell lymphoma has been discontinued due to unsatisfactory efficacy. The low risk of side effects, accessibility, and effectiveness of alisertib makes it a new promising anticancer therapy and further mechanistic and clinical studies are warranted.\n                  <\/jats:p>","DOI":"10.1111\/1440-1681.12571","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T22:47:17Z","timestamp":1458600437000},"page":"585-601","source":"Crossref","is-referenced-by-count":40,"title":["An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor"],"prefix":"10.1111","volume":"43","author":[{"given":"Cameron T","family":"Durlacher","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of South Florida Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shanghai Children's Hospital Shanghai Jiao Tong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Wu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery The First People's Hospital of Shunde Affiliated to Southern Medical University Shunde Foshan Guangdong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Xu","family":"He","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Key Laboratory for Regenerative Medicine Stem Cell and Tissue Engineering Research Centre &amp; Sino\u2010US Joint Laboratory for Medical Sciences Guizhou Medical University Guiyang Guizhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u2010Feng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of South Florida Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90374-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0208"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.02.006"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.14"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2005.02.021"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.18.9591"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00178"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2015.00050"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140275"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.632"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1073-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1526"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20633"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.7988"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1502"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3284-8"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2295w"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.022"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.11.006"},{"key":"e_1_2_10_21_1","first-page":"295","article-title":"Aurora\u2010A kinase as a promising therapeutic target in cancer","volume":"5","author":"D'Assoro AB","year":"2015","journal-title":"Front. Oncol."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00278"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1536"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0623"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-259523"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.255554.114"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2013.0392"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015792"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.033"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/2496"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.21.13766"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1393-8"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00290"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.11.063"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1279"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2179"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.005"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0431"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2775"},{"key":"e_1_2_10_40_1","first-page":"1420","article-title":"Activation and overexpression of centrosome kinase BTAK\/Aurora\u2010A in human ovarian cancer","volume":"9","author":"Gritsko TM","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28434"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.325"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1187"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.05.012"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1615"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.444"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.08.050"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00225"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2014.08.006"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3916"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2016.02.016"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2015.00014"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403029200"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2005.00863.x"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm4025"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2015.08.008"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2014.10.002"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm061335f"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009615666150421110401"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800984v"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E04-10-0891"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3001"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1003"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.60"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.652303"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0444"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049076m"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060897w"},{"key":"e_1_2_10_69_1","first-page":"1027","article-title":"The pan\u2010inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial\u2010to\u2010mesenchymal transition in human breast cancer cells","volume":"9","author":"Li JP","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_70_1","first-page":"1293","article-title":"Danusertib, a potent pan\u2010Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K\/Akt\/mTOR\u2010mediated signaling pathway in human gastric cancer AGS and NCI\u2010N78 cells","volume":"9","author":"Yuan CX","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161126018"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu566"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11404.x"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6655"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1445"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr451"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1592"},{"key":"e_1_2_10_78_1","first-page":"1","article-title":"A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk","volume":"2015","author":"Hay AE","year":"2015","journal-title":"Lymphoma"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901913s"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1076-8"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0754"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0641-1"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0915"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901870q"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0609"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0306-7"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073700"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq344"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.019"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13333"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0325"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2144"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.020"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113773"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb200508b"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2010.01218.x"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800958779"},{"key":"e_1_2_10_98_1","first-page":"487","article-title":"Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI\u2010N78 cells","volume":"9","author":"Yuan CX","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_99_1","first-page":"425","article-title":"Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells","volume":"9","author":"Ding YH","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_100_1","first-page":"575","article-title":"Alisertib induces cell cycle arrest and autophagy and suppresses epithelial\u2010to\u2010mesenchymal transition involving PI3K\/Akt\/mTOR and sirtuin 1\u2010mediated signaling pathways in human pancreatic cancer cells","volume":"9","author":"Wang F","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_101_1","first-page":"1555","article-title":"Pro\u2010apoptotic and pro\u2010autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U\u20102 OS and MG\u201063 cells through the activation of mitochondria\u2010mediated pathway and inhibition of p38 MAPK\/PI3K\/Akt\/mTOR signaling pathway","volume":"9","author":"Niu NK","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_102_1","first-page":"1627","article-title":"The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2\/M arrest, apoptosis, and autophagy via p38 MAPK and Akt\/mTOR signaling pathways in human breast cancer cells","volume":"9","author":"Li JP","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2383"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0027"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201201378"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2782-3"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0386"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312807666131229122359"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2305-8"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108758"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2015.08.007"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0571"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0589"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0121-6"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3251"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0050-9"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202359"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0258-y"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-015-0114-8"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.026"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1267-8"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2313"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28277"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.032"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01499.x"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.10.1.77"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4889"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70051-3"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.06.040"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0328-9"},{"key":"e_1_2_10_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_2_10_132_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"e_1_2_10_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9831-9"},{"key":"e_1_2_10_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1618-8"},{"key":"e_1_2_10_135_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121343"},{"key":"e_1_2_10_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0795-y"},{"key":"e_1_2_10_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22430"},{"key":"e_1_2_10_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov017"},{"key":"e_1_2_10_139_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv090.6"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:58:53Z","timestamp":1695545933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":138,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/1440-1681.12571"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12571","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]}}}